Corvus Pharmaceuticals (CRVS) Accounts Payables (2015 - 2026)

Corvus Pharmaceuticals' Accounts Payables history runs 12 years deep, the most recent figure standing at $4.7 million for Q1 2026.

• On a quarterly basis, Accounts Payables rose 259.1% year-over-year to $4.7 million in Q1 2026; TTM through Mar 2026 was $4.7 million, a 259.1% increase from a year earlier, with the FY2025 full-year figure at $2.5 million, down 3.52% from the prior year.
• Accounts Payables improved to $4.7 million in Q1 2026 per CRVS's latest filing, from $2.5 million in the prior quarter.
• Across five years, Accounts Payables topped out at $4.7 million in Q1 2026 and bottomed at $730000.0 in Q2 2025.
• The 5-year median for Accounts Payables is $1.9 million (2024), against an average of $2.1 million.
• Across the five-year window, Accounts Payables tumbled 66.78% in 2023 and surged 259.1% in 2026, its largest moves.
• Year by year, Accounts Payables stood at $2.0 million in 2022, then retreated by 22.82% to $1.5 million in 2023, then surged by 69.31% to $2.6 million in 2024, then retreated by 3.52% to $2.5 million in 2025, then jumped by 88.56% to $4.7 million in 2026.
• Per Business Quant, the three latest CRVS Accounts Payables figures stand at $4.7 million (Q1 2026), $2.5 million (Q4 2025), and $1.2 million (Q3 2025).